Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.

ABSTRACT: Hepatitis C virus (HCV) poses a major health threat to the world. The recent development of direct-acting antivirals (DAAs) against HCV has markedly improved the response rate of HCV and reduced the side effects in comparison to the interferon-based therapy. Despite this therapeutic advance, there is still a need to develop new inhibitors that target different stages of the HCV life cycle because of various limitations of the current regimens. In this study, we performed a quantitative high throughput screening of the Molecular Libraries Small Molecule Repository (MLSMR) of ∼350,000 chemicals for novel HCV inhibitors using our previously developed cell-based HCV infection assay. Following confirmation and structural clustering analysis, we narrowed down to 158 compounds from the initial ∼3

SUBMITTER: Hu Z 

PROVIDER: S-EPMC4684727 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature